Charles River Labs stock edges lower as investors weigh FY 2026 guidance and conference schedule
Published on 09/11/2026 at 16:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International, Inc. stock (ISIN US1591881009) finished the September 8, 2026 session at 283.98 USD on the NYSE, down 1.4 percent from the prior close in a broadly weaker US equity market. According to Zacks data cited in a recent stock wrap, the Dow Jones Industrial Average declined 0.8 percent that day, so Charles River Labs moved somewhat more strongly to the downside than the wider blue-chip index.
Recent trading range and valuation signals
Per exchange figures summarized in an institutional holding update on MarketBeat, Charles River Labs stock has traded over the past 12 months in a one year range between 144.26 USD and 303.30 USD, placing the September 8, 2026 close of 283.98 USD in the upper part of its 52 week band.MarketBeat In the same ad-hoc-news stock wrap, the 283.98 USD closing level was described as standing slightly above a recent average analyst target of around 281 USD, indicating that the shares were trading just above consensus fair value at that point.
In more recent intraday action, MarketBeat data show that Charles River Labs opened at 272.68 USD on September 11, 2026, implying that the stock was about 4.0 percent below the September 8, 2026 close at the start of the latest session.MarketBeat For investors, this pullback from the upper end of the 52 week range is one of the key chart signals when weighing upside against the company’s guidance and analyst expectations.
FY 2026 EPS guidance and analyst expectations
According to a recent overview of the stock on MarketBeat dated September 11, 2026, Charles River Laboratories has set its fiscal year 2026 guidance at 11.15 to 11.45 USD in earnings per share (EPS).MarketBeat Sell side analysts captured in the same dataset on that date anticipate that the company will post EPS of 11.33 USD for the current year, which sits roughly in the middle of the company’s guidance corridor.
The same MarketBeat compilation notes that eleven research analysts currently rate Charles River Labs stock as Buy, three as Hold and one as Sell, resulting in a consensus rating of ‘Moderate Buy’ and a consensus target price of 259.44 USD.MarketBeat Comparing this 259.44 USD consensus target with the September 8, 2026 close of 283.98 USD suggests that the shares were trading about 9.5 percent above the average analyst price objective at that time, underscoring that the market is already pricing in a degree of optimism beyond the published targets.
Within the analyst community, CLSA recently downgraded Charles River Labs from ‘outperform’ to ‘hold’ and set a specific price target of 219.00 USD on the stock.MarketBeat This individual target sits significantly below both the 259.44 USD consensus and the recent trading levels above 270 USD, and therefore represents a notable cautionary signal for more value oriented investors who see limited upside at current prices.
Operational backdrop and investor conferences
While the detailed quarterly revenue and margin figures are not fully broken out in the very latest week filtered sources, several recent coverage notes tie the current share price performance back to the company’s ability to deliver on its FY 2026 EPS guidance range. In particular, the MarketBeat summary explicitly anchors the guidance in the context of sell side estimates as of September 11, 2026, highlighting that expectations are aligned with management’s corridor.MarketBeat For investors, the key operational question over the coming quarters will be whether revenue growth and margins in the company’s preclinical services and other segments are sufficient to support EPS at or above the midpoint of 11.30 USD.
On the capital markets side, Charles River Laboratories announced on September 11, 2026 that it will present at two upcoming investor conferences organized by Morgan Stanley and Baird.Investing News According to that announcement, the company plans to participate in these events on September 14, 2026 and a subsequent date, giving management a platform to discuss strategy, demand trends and its fiscal 2026 outlook with institutional investors. A brief note on StockTitan’s market news feed on September 11, 2026 also flagged the conference participation as a sentiment relevant event for NYSE listed Charles River Labs shares.StockTitan
Conference appearances do not directly change fundamentals, but they often provide incremental information on order trends, pricing, regulatory developments and capital allocation. For a stock trading above consensus price targets and with a ‘Moderate Buy’ rating profile, any commentary that reinforces or challenges the FY 2026 EPS guidance of 11.15 to 11.45 USD will be closely scrutinized by the market.
Market positioning and peer context
Beyond its own guidance and analyst coverage, Charles River Laboratories also features as a meaningful component in healthcare themed exchange traded funds. A recent analysis on The Motley Fool discussed the composition of the Invesco S&P 500 Equal Weight Health Care ETF, noting that Charles River Laboratories International accounted for approximately 2.2 percent of that ETF’s holdings as of late August 2026.The Motley Fool This inclusion underscores the company’s role as a mid sized but strategically important player in the broader healthcare and life sciences ecosystem.
ETF and index participation can reinforce liquidity and investor attention, but they also mean that Charles River Labs stock can be influenced by sector level flows and sentiment in addition to company specific factors. For example, strong inflows into healthcare funds could support the shares even if individual earnings revisions are modest, whereas sector wide risk off phases may weigh on the stock despite solid operational performance.
On the risk side, the CLSA downgrade to ‘hold’ with a 219.00 USD target highlights that not all analysts see substantial upside from current levels and that valuation, regulatory complexity and competitive dynamics in preclinical and related services remain key considerations.MarketBeat For investors, balancing this more cautious view against the broader ‘Moderate Buy’ consensus and the company’s own EPS guidance is central to deciding whether the risk reward profile remains attractive.
Stock level as of the latest sessions
As of the most recently completed trading day with detailed figures, Charles River Labs stock closed at 283.98 USD on the NYSE on September 8, 2026, after trading between roughly 280.10 USD and 287.40 USD during that session, with volume in the hundreds of thousands of shares. In the context of a 52 week range between 144.26 USD and 303.30 USD and a consensus price target of 259.44 USD, this places the shares near the upper end of their yearly band and above the average analyst objective, a positioning that makes upcoming conference commentary and delivery on the FY 2026 EPS guidance range of 11.15 to 11.45 USD particularly relevant for holders.
Charles River Labs stock key data
- Company: Charles River Laboratories International, Inc.
- ISIN: US1591881009
- Ticker: CRL
- Trading venue: NYSE
- Price (as of September 8, 2026): 283.98 USD
- Market capitalization: [value not substantiated in available week filtered sources]
- Sector / Industry: Health care / Life sciences services
- Index membership: S&P 500
